Blood Concentration of Cabazitaxel in a Patient Whose General Condition Worsened with Concomitant Use of Clarithromycin
We encountered a case in which the general condition of a patient receiving cabazitaxel worsened with concomitant use of clarithromycin. Cabazitaxel is metabolized mainly by CYP3A4, and the frequency of adverse events is known to increase with increasing exposure. Although these drugs are not often...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-07-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://beta.karger.com/Article/FullText/530547 |
| _version_ | 1797745905205510144 |
|---|---|
| author | Shigeaki Katsumi Takuya Araki Hideaki Yashima Yoshiyuki Miyazawa Kazuhiro Suzuki Koujirou Yamamoto |
| author_facet | Shigeaki Katsumi Takuya Araki Hideaki Yashima Yoshiyuki Miyazawa Kazuhiro Suzuki Koujirou Yamamoto |
| author_sort | Shigeaki Katsumi |
| collection | DOAJ |
| description | We encountered a case in which the general condition of a patient receiving cabazitaxel worsened with concomitant use of clarithromycin. Cabazitaxel is metabolized mainly by CYP3A4, and the frequency of adverse events is known to increase with increasing exposure. Although these drugs are not often quantified in daily practice, we quantified them because we considered it possible that the blood concentration of cabazitaxel had increased due to CYP3A4 inhibition of clarithromycin and that cabazitaxel-related adverse events had occurred. However, the concentration of cabazitaxel was not increased and we attributed the patient’s deterioration to decreased tolerability of cabazitaxel. At least at a trough concentration of 70 ng/mL, which is the trough concentration when a normal dose of clarithromycin is administered, clarithromycin does not appear to have a significant effect on the blood concentration of cabazitaxel. This case suggests that the administration of the normal dose of clarithromycin might be relatively safe in patients receiving cabazitaxel. |
| first_indexed | 2024-03-12T15:29:34Z |
| format | Article |
| id | doaj.art-701b7126388c4c65a12ee46bcf8c0fa9 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-03-12T15:29:34Z |
| publishDate | 2023-07-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-701b7126388c4c65a12ee46bcf8c0fa92023-08-10T08:11:07ZengKarger PublishersCase Reports in Oncology1662-65752023-07-0116149750310.1159/000530547530547Blood Concentration of Cabazitaxel in a Patient Whose General Condition Worsened with Concomitant Use of ClarithromycinShigeaki Katsumi0Takuya Araki1Hideaki Yashima2Yoshiyuki Miyazawa3Kazuhiro Suzuki4Koujirou Yamamoto5Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, Maebashi, JapanDepartment of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, Maebashi, JapanDepartment of Pharmacy, Gunma University Hospital, Maebashi, JapanDepartment of Urology, Gunma University Graduate School of Medicine, Maebashi, JapanDepartment of Urology, Gunma University Graduate School of Medicine, Maebashi, JapanDepartment of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, Maebashi, JapanWe encountered a case in which the general condition of a patient receiving cabazitaxel worsened with concomitant use of clarithromycin. Cabazitaxel is metabolized mainly by CYP3A4, and the frequency of adverse events is known to increase with increasing exposure. Although these drugs are not often quantified in daily practice, we quantified them because we considered it possible that the blood concentration of cabazitaxel had increased due to CYP3A4 inhibition of clarithromycin and that cabazitaxel-related adverse events had occurred. However, the concentration of cabazitaxel was not increased and we attributed the patient’s deterioration to decreased tolerability of cabazitaxel. At least at a trough concentration of 70 ng/mL, which is the trough concentration when a normal dose of clarithromycin is administered, clarithromycin does not appear to have a significant effect on the blood concentration of cabazitaxel. This case suggests that the administration of the normal dose of clarithromycin might be relatively safe in patients receiving cabazitaxel.https://beta.karger.com/Article/FullText/530547cytochrome p450drug-drug interactioncabazitaxelclarithromycinblood concentration |
| spellingShingle | Shigeaki Katsumi Takuya Araki Hideaki Yashima Yoshiyuki Miyazawa Kazuhiro Suzuki Koujirou Yamamoto Blood Concentration of Cabazitaxel in a Patient Whose General Condition Worsened with Concomitant Use of Clarithromycin Case Reports in Oncology cytochrome p450 drug-drug interaction cabazitaxel clarithromycin blood concentration |
| title | Blood Concentration of Cabazitaxel in a Patient Whose General Condition Worsened with Concomitant Use of Clarithromycin |
| title_full | Blood Concentration of Cabazitaxel in a Patient Whose General Condition Worsened with Concomitant Use of Clarithromycin |
| title_fullStr | Blood Concentration of Cabazitaxel in a Patient Whose General Condition Worsened with Concomitant Use of Clarithromycin |
| title_full_unstemmed | Blood Concentration of Cabazitaxel in a Patient Whose General Condition Worsened with Concomitant Use of Clarithromycin |
| title_short | Blood Concentration of Cabazitaxel in a Patient Whose General Condition Worsened with Concomitant Use of Clarithromycin |
| title_sort | blood concentration of cabazitaxel in a patient whose general condition worsened with concomitant use of clarithromycin |
| topic | cytochrome p450 drug-drug interaction cabazitaxel clarithromycin blood concentration |
| url | https://beta.karger.com/Article/FullText/530547 |
| work_keys_str_mv | AT shigeakikatsumi bloodconcentrationofcabazitaxelinapatientwhosegeneralconditionworsenedwithconcomitantuseofclarithromycin AT takuyaaraki bloodconcentrationofcabazitaxelinapatientwhosegeneralconditionworsenedwithconcomitantuseofclarithromycin AT hideakiyashima bloodconcentrationofcabazitaxelinapatientwhosegeneralconditionworsenedwithconcomitantuseofclarithromycin AT yoshiyukimiyazawa bloodconcentrationofcabazitaxelinapatientwhosegeneralconditionworsenedwithconcomitantuseofclarithromycin AT kazuhirosuzuki bloodconcentrationofcabazitaxelinapatientwhosegeneralconditionworsenedwithconcomitantuseofclarithromycin AT koujirouyamamoto bloodconcentrationofcabazitaxelinapatientwhosegeneralconditionworsenedwithconcomitantuseofclarithromycin |